CBU group leader Eivind Valen and Emma Haapaniemi from NCMM got the grant for the project “CRISPR-Cas9 corrected T cells for personalized therapy”. It aims to develop novel methods for personalized gene therapy. Specifically, they will create a computational and clinical CRISPR-Cas9-based editing platform for primary immunodeficiency disease therapy. The project will provide both specific therapies for these diseases and general tools for personalized gene therapy.